TRITON TIMI 38

OBJECTIVE: To evaluate prasugrel compared with clopidogrel in patients with acute coronary syndromes.

View/Download
_______________________________________________________________________________

1. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the Trial to assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E. Am Heart J 2006;152(4):627-35.
   | Abstract | Request Reprints |
   
   
2. Prasugrel versus clopidogrel in patients with acute coronary syndromes. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, for the TRITON-TIMI 38 Investigators. NEJM 2007;357:2001-2015.
   | Abstract | Request Reprints |
   
   
3. A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Wiviott SD, Braunwald E, Murphy SA, Antman EM. Am J Cardiol 2008;101:1367-70.
   | Abstract | Request Reprints |
   
   
4. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Wiviott SD, Braunwald E, McCabe CH, et al. Lancet 2008;371:1353-63.
   | Abstract | Request Reprints |
   
   
5. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Antman EM, Wiviott SD, Murphy SA, et al. J Am Coll Cardiol 2008;51:2028-33.
   | Abstract | Request Reprints |
   
   
6. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Murphy SA, Antman EM, Wiviott SD, et al. Eur Heart J 2008;29:2473-9.
   | Abstract | Request Reprints |
   
   
7. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Circulation 2008;118:1626-36.
   | Abstract | Request Reprints | SLIDES |